by Richard Daverman, PhD
September 7, 2012 -- Triplex International Biosciences (China) Co., a Xiamen maker of medical diagnostic reagents and instruments, received a $50 million capital infusion from private-equity firm RRJ Capital. According to unnamed sources, the investment will buy a stake in Triplex that is somewhere in the 11% to 19% range. Triplex makes diagnostic tests for hepatitis B and C and various forms of cancer. RRJ Capital is based in Hong Kong and Singapore. More details....
